Systemic sclerosis & Raynaud's
Circulating monocytes from systemic sclerosis patients with progressive interstitial lung disease preferentially express M2 phenotype markers: in vitro and ex vivo study
Authors' conclusion
Cultured MDMs from circulating monocytes in SSc pts with prog-ILD show markedly increased profibrotic biomarkers and mediator expression, indicating an enhanced fibrotic phenotype compared to non-prog and no-ILD SSc pts.
Study context
- Population
- Systemic sclerosis (SSc) patients with progressive interstitial lung disease (ILD), non-progressive ILD or without ILD, and age-matched healthy controlsSSc pts plus 20 controls
- Participants
- 55 patients
- Comparison
- SSc with progressive ILD vs non-progressive ILD vs no ILD
- Healthy controlsn = 20
- Outcome
- Phenotype and functional profibrotic M2 markers in circulating monocytes and cultured MDMs
Methodological detailsin vitro and ex vivo, age-matched healthy controls
- In vitro and ex vivo
- Age-matched healthy controls
Main finding
As reported in the abstract
- Higher % of TLR4+CD204+CD206+CD163+ monocytes in prog-ILD vs no-prog-ILD, and significantly higher vs no-ILD
- Monocyte-derived macrophages (MDMs) from prog-ILD: significantly higher gene expression and protein synthesis of TGFβ1, and significantly higher protein synthesis of MerTK, CD206, IL4 and CCL18 vs no-prog-ILD
- Gene expression and protein synthesis of TGFβ1, TLR4, CD206, CD163, ARG1, MerTK and IL6 significantly increased in prog-ILD vs no-ILD MDMs
- Flow cytometry in 36 SSc pts; MDMs analysed in 29 SSc pts
Original publication
Circulating monocytes from systemic sclerosis patients with progressive interstitial lung disease preferentially express M2 phenotype markers: in vitro and ex vivo study. RMD Open. Published 11 December 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →